Skip to main content
Top
Published in: Journal of Translational Medicine 1/2020

Open Access 01-12-2020 | Ankylosing Spondylitis | Research

Positive association of Parkinson’s disease with ankylosing spondylitis: a nationwide population-based study

Authors: Fu-Chiang Yeh, Hsiang-Cheng Chen, Yu-Ching Chou, Cheng-Li Lin, Chia-Hung Kao, Hsin-Yi Lo, Feng-Cheng Liu, Tse-Yen Yang

Published in: Journal of Translational Medicine | Issue 1/2020

Login to get access

Abstract

Background

Ankylosing spondylitis (AS) is characterized by excessive production of inflammatory cytokines. Recent evidence suggests that inflammation underlies the neurodegenerative process of Parkinson’s disease (PD). Whether AS has an influence on the development of PD is unclear. We aimed to examine a relationship, if any exists between AS and PD.

Methods

A population-based matched cohort study was performed using data from the 2000–2010 Taiwan National Health Insurance database. 6440 patients with AS and 25,760 randomly selected, age- and sex-matched controls were included in this study. The risk of PD in the AS cohort was evaluated by using a Cox model.

Results

This study revealed a positive association between AS and the risk of PD regardless of sex and age (aHR 1.75, p < .001). Particularly, AS cohort to non-AS cohort relative risk of PD significantly increased for the patients aged below 49 and above 65 years (aHR 4.70, p < .001; aHR 1.69, p < .001, respectively) and the patients with and without comorbidities (aHR 1.61, p < .001; aHR 2.71, p < .001, respectively). Furthermore, NSAID use was associated with lower risk of PD (aHR 0.69, p < .05). However, the risk of PD was higher (aHR 2.40, p < .01) in patients with AS receiving immunosuppressants than in those not receiving (aHR 1.70, p < .001).

Conclusions

Patients with AS had an increased risk of PD which might be related to underlying chronic inflammation. Further research is required to elucidate the underlying mechanism.
Literature
1.
go back to reference Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.CrossRef Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.CrossRef
2.
go back to reference Liu W, Wu YH, Zhang L, Liu XY, Xue B, Wang Y, Liu B, Jiang Q, Kwang HW, Wu DJ. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8:17362–76.PubMedPubMedCentral Liu W, Wu YH, Zhang L, Liu XY, Xue B, Wang Y, Liu B, Jiang Q, Kwang HW, Wu DJ. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8:17362–76.PubMedPubMedCentral
3.
go back to reference Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, Van Gassen S, Martens L, Smith D, Harcken C, Wahle J, Wang CT, Verheugen E, Schryvers N, Varkas G, Cypers H, Wittoek R, Piette Y, Gyselbrecht L, Van Calenbergh S, Van den Bosch F, Saeys Y, Nabozny G, Elewaut D. RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10:9.CrossRef Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, Van Gassen S, Martens L, Smith D, Harcken C, Wahle J, Wang CT, Verheugen E, Schryvers N, Varkas G, Cypers H, Wittoek R, Piette Y, Gyselbrecht L, Van Calenbergh S, Van den Bosch F, Saeys Y, Nabozny G, Elewaut D. RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10:9.CrossRef
4.
go back to reference El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22:554–60.CrossRef El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22:554–60.CrossRef
5.
go back to reference Jang HD, Park JS, Kim DW, Han K, Shin BJ, Lee JC, Choi SW, Suh SW, Yang JH, Park SY, Cho WJ, Hong JY. Relationship between dementia and ankylosing spondylitis: a nationwide, population-based, retrospective longitudinal cohort study. PLoS ONE. 2019;14:e0210335.CrossRef Jang HD, Park JS, Kim DW, Han K, Shin BJ, Lee JC, Choi SW, Suh SW, Yang JH, Park SY, Cho WJ, Hong JY. Relationship between dementia and ankylosing spondylitis: a nationwide, population-based, retrospective longitudinal cohort study. PLoS ONE. 2019;14:e0210335.CrossRef
6.
go back to reference Lin CW, Huang YP, Chiu YH, Ho YT, Pan SL. Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. PLoS ONE. 2014;9:e94027.CrossRef Lin CW, Huang YP, Chiu YH, Ho YT, Pan SL. Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. PLoS ONE. 2014;9:e94027.CrossRef
7.
go back to reference Park JS, Jang HD, Hong JY, Park YS, Han K, Suh SW, Park SY, Kim BT. Impact of ankylosing spondylitis on depression: a nationwide cohort study. Sci Rep. 2019;9:6736.CrossRef Park JS, Jang HD, Hong JY, Park YS, Han K, Suh SW, Park SY, Kim BT. Impact of ankylosing spondylitis on depression: a nationwide cohort study. Sci Rep. 2019;9:6736.CrossRef
8.
go back to reference Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends Mol Med. 2003;9:126–32.CrossRef Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends Mol Med. 2003;9:126–32.CrossRef
9.
go back to reference Caggiu E, Arru G, Hosseini S, Niegowska M, Sechi G, Zarbo IR, Sechi LA. Inflammation, infectious triggers, and Parkinson’s disease. Front Neurol. 2019;10:122.CrossRef Caggiu E, Arru G, Hosseini S, Niegowska M, Sechi G, Zarbo IR, Sechi LA. Inflammation, infectious triggers, and Parkinson’s disease. Front Neurol. 2019;10:122.CrossRef
10.
go back to reference Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine. 2012;60:762–6.CrossRef Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine. 2012;60:762–6.CrossRef
11.
go back to reference Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci. 2014;8:369.PubMedPubMedCentral Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci. 2014;8:369.PubMedPubMedCentral
12.
go back to reference Vesely B, Dufek M, Thon V, Brozman M, Kiralova S, Halaszova T, Koritakova E, Rektor I. Interleukin 6 and complement serum level study in Parkinson’s disease. J Neural Transm (Vienna). 2018;125:875–81.CrossRef Vesely B, Dufek M, Thon V, Brozman M, Kiralova S, Halaszova T, Koritakova E, Rektor I. Interleukin 6 and complement serum level study in Parkinson’s disease. J Neural Transm (Vienna). 2018;125:875–81.CrossRef
13.
go back to reference Pereira JR, Santos LVD, Santos RMS, Campos ALF, Pimenta AL, de Oliveira MS, Bacheti GG, Rocha NP, Teixeira AL, Christo PP, Scalzo PL. IL-6 serum levels are elevated in Parkinson’s disease patients with fatigue compared to patients without fatigue. J Neurol Sci. 2016;370:153–6.CrossRef Pereira JR, Santos LVD, Santos RMS, Campos ALF, Pimenta AL, de Oliveira MS, Bacheti GG, Rocha NP, Teixeira AL, Christo PP, Scalzo PL. IL-6 serum levels are elevated in Parkinson’s disease patients with fatigue compared to patients without fatigue. J Neurol Sci. 2016;370:153–6.CrossRef
14.
go back to reference Green HF, Khosousi S, Svenningsson P. Plasma IL-6 and IL-17A Correlate With Severity Of Motor And Non-Motor Symptoms in Parkinson’s disease. J Parkinsons Dis. 2019;9:705–9.CrossRef Green HF, Khosousi S, Svenningsson P. Plasma IL-6 and IL-17A Correlate With Severity Of Motor And Non-Motor Symptoms in Parkinson’s disease. J Parkinsons Dis. 2019;9:705–9.CrossRef
15.
go back to reference Schroder JB, Pawlowski M, Meyer Zu Horste G, Gross CC, Wiendl H, Meuth SG, Ruck T, Warnecke T. Immune cell activation in the cerebrospinal fluid of patients With Parkinson’s disease. Front Neurol. 2018;9:1081.CrossRef Schroder JB, Pawlowski M, Meyer Zu Horste G, Gross CC, Wiendl H, Meuth SG, Ruck T, Warnecke T. Immune cell activation in the cerebrospinal fluid of patients With Parkinson’s disease. Front Neurol. 2018;9:1081.CrossRef
16.
go back to reference Chang CC, Lin TM, Chang YS, Chen WS, Sheu JJ, Chen YH, Chen JH. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med. 2018;50:83–90.CrossRef Chang CC, Lin TM, Chang YS, Chen WS, Sheu JJ, Chen YH, Chen JH. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med. 2018;50:83–90.CrossRef
17.
go back to reference Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis. 2012;10:277–84.CrossRef Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis. 2012;10:277–84.CrossRef
18.
go back to reference Wu SH, Chuang E, Chuang TY, Lin CL, Lin MC, Yen DJ, Kao CH. A nationwide population-based cohort study of migraine and organic-psychogenic erectile dysfunction. Medicine (Baltimore). 2016;95:e3065.CrossRef Wu SH, Chuang E, Chuang TY, Lin CL, Lin MC, Yen DJ, Kao CH. A nationwide population-based cohort study of migraine and organic-psychogenic erectile dysfunction. Medicine (Baltimore). 2016;95:e3065.CrossRef
19.
go back to reference Kao CC, Lin CL, Huang WY, Cha TL, Lin TY, Shen CH, Kao CH. Association between inflammatory bowel disease and erectile dysfunction: a nationwide population-based study. Inflamm Bowel Dis. 2016;22:1065–70.CrossRef Kao CC, Lin CL, Huang WY, Cha TL, Lin TY, Shen CH, Kao CH. Association between inflammatory bowel disease and erectile dysfunction: a nationwide population-based study. Inflamm Bowel Dis. 2016;22:1065–70.CrossRef
20.
go back to reference Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int. 2016;27:2117–26.CrossRef Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int. 2016;27:2117–26.CrossRef
21.
go back to reference Walsh JA, Song X, Kim G, Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol. 2018;37:1869–78.CrossRef Walsh JA, Song X, Kim G, Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol. 2018;37:1869–78.CrossRef
22.
go back to reference Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korbo L, Olsen JH. Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology. 2009;73:1462–8.CrossRef Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korbo L, Olsen JH. Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology. 2009;73:1462–8.CrossRef
23.
go back to reference Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, Blauwendraat C, Thompson WK, Hernandez DG, Djurovic S, Schork AJ, Bettella F, Ellinghaus D, Franke A, Lie BA, McEvoy LK, Karlsen TH, Lesage S, Morris HR, Brice A, Wood NW, Heutink P, Hardy J, Singleton AB, Dale AM, Gasser T, Andreassen OA, Sharma M. International Parkinson’s Disease Genomics Consortium NABEC and United Kingdom Brain Expression Consortium I. Genome-wide pleiotropy between parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780–92.CrossRef Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, Blauwendraat C, Thompson WK, Hernandez DG, Djurovic S, Schork AJ, Bettella F, Ellinghaus D, Franke A, Lie BA, McEvoy LK, Karlsen TH, Lesage S, Morris HR, Brice A, Wood NW, Heutink P, Hardy J, Singleton AB, Dale AM, Gasser T, Andreassen OA, Sharma M. International Parkinson’s Disease Genomics Consortium NABEC and United Kingdom Brain Expression Consortium I. Genome-wide pleiotropy between parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780–92.CrossRef
24.
go back to reference Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS and Group MS. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48.CrossRef Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS and Group MS. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48.CrossRef
25.
go back to reference Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282–98.CrossRef Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282–98.CrossRef
26.
go back to reference Moon KH, Kim YT. Medical treatment of ankylosing spondylitis. Hip Pelvis. 2014;26:129–35.CrossRef Moon KH, Kim YT. Medical treatment of ankylosing spondylitis. Hip Pelvis. 2014;26:129–35.CrossRef
27.
go back to reference Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol. 2011;18:1336–42.CrossRef Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol. 2011;18:1336–42.CrossRef
28.
go back to reference Poly TN, Islam MMR, Yang HC, Li YJ. Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol. 2019;75:99–108.CrossRef Poly TN, Islam MMR, Yang HC, Li YJ. Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol. 2019;75:99–108.CrossRef
29.
go back to reference Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine (Baltimore). 2018;97:e12172.CrossRef Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine (Baltimore). 2018;97:e12172.CrossRef
30.
go back to reference Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles NS. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018;5:870–5.CrossRef Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles NS. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018;5:870–5.CrossRef
31.
go back to reference Sung YF, Liu FC, Lin CC, Lee JT, Yang FC, Chou YC, Lin CL, Kao CH, Lo HY, Yang TY. Reduced risk of Parkinson disease in patients with rheumatoid arthritis: a nationwide population-based study. Mayo Clin Proc. 2016;91:1346–53.CrossRef Sung YF, Liu FC, Lin CC, Lee JT, Yang FC, Chou YC, Lin CL, Kao CH, Lo HY, Yang TY. Reduced risk of Parkinson disease in patients with rheumatoid arthritis: a nationwide population-based study. Mayo Clin Proc. 2016;91:1346–53.CrossRef
32.
go back to reference Liu FC, Huang WY, Lin TY, Shen CH, Chou YC, Lin CL, Lin KT, Kao CH. Inverse association of Parkinson disease with systemic lupus erythematosus: a nationwide population-based study. Medicine (Baltimore). 2015;94:e2097.CrossRef Liu FC, Huang WY, Lin TY, Shen CH, Chou YC, Lin CL, Lin KT, Kao CH. Inverse association of Parkinson disease with systemic lupus erythematosus: a nationwide population-based study. Medicine (Baltimore). 2015;94:e2097.CrossRef
33.
go back to reference Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005;65:1575–83.CrossRef Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005;65:1575–83.CrossRef
34.
go back to reference Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64:576–80.CrossRef Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64:576–80.CrossRef
35.
go back to reference Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr. 2008;62:908–15.CrossRef Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr. 2008;62:908–15.CrossRef
36.
go back to reference van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, van Laar T, Kromhout H, Vermeulen R. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking. PLoS ONE. 2014;9:e95297.CrossRef van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, van Laar T, Kromhout H, Vermeulen R. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking. PLoS ONE. 2014;9:e95297.CrossRef
Metadata
Title
Positive association of Parkinson’s disease with ankylosing spondylitis: a nationwide population-based study
Authors
Fu-Chiang Yeh
Hsiang-Cheng Chen
Yu-Ching Chou
Cheng-Li Lin
Chia-Hung Kao
Hsin-Yi Lo
Feng-Cheng Liu
Tse-Yen Yang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2020
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02629-w

Other articles of this Issue 1/2020

Journal of Translational Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.